Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500432 | 1.00 | PRMT6 (0.38) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL23042587 | 0.94 | PRMT6 (0.40) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL26238542 | 0.91 | PRMT6 (0.43) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL29772226 | 0.91 | PRMT6 (0.43) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL23042726 | 0.91 | PRMT6 (0.43) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL29827355 | 0.91 | PRMT6 (0.41) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL30773491 | 0.89 | PRMT6 (0.40) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL29772228 | 0.89 | PRMT6 (0.36) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| Fumaric Acid SCHEMBL29772229 | 0.88 | PRMT6 (0.41) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 | |
| SCHEMBL19500433 | 0.87 | PRMT6 (0.38) | PRMT6CYP1A2HTR1ACYP2D6ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | PRMT6 3553/4885CYP1A2 4778/4885HTR1A 3636/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | PRMT6 3553/4885CYP1A2 4778/4885HTR1A 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.